SPRUCE BIOSCIENCES, INC. (SPRB)

Pharmaceutical Preparations · market cap $136M · as of 2026-07-13

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-09 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Spruce Biosciences (SPRB) is a clinical-stage pharmaceutical company with a market cap of ~$138M and 9 employees, built around a single asset: SPR001, a Phase 2 candidate for Congenital Adrenal Hyperplasia (CAH). The company holds ~$54.1M in cash with an estimated 18.6-month runway, and the next formal public touchpoint is an August 13, 2026 earnings call.

The catalyst path

2026-11-09 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
SPR001	Phase 2	Congenital Adrenal Hyperplasia

Price & technical context

3-month

-12.9%

6-month

-35.9%

12-month

+407.5%

52-wk range

$8.60–$182.60

vs 50-day MA

-12.0%

vs 200-day MA

-24.1%

Realized vol

286.6%

Max drawdown

-99.8%

Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for SPRB (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.